申请人:CELLCENTRIC LTD
公开号:US10696666B2
公开(公告)日:2020-06-30
A compound which is an arylimidazolyl isoxazole of formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.
一种化合物,它是式(I)的芳基咪唑基异噁唑:式(I))或其药学上可接受的盐。该化合物具有调节 p300 和/或 CBP 活性的活性,可用于治疗癌症,尤其是前列腺癌。